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Infarct Size Limitation by a New Na1-H1 Exchange Inhibitor, Hoe
642: Difference From Preconditioning in the Role of Protein Kinase C
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MAHIKO GOTO, MD, KAZUAKI SHIMAMOTO, MD, PHD
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Objectives. This study examined the effect of a new specific
Na1-H1 exchange inhibitor, Hoe 642, on infarct size and the
protective role of protein kinase C (PKC) by this agent. In
addition, we assessed the possible alteration of Hoe 642–induced
cardioprotection by commonly used animal anesthetic drugs.
Background. Earlier studies on the contribution of Na1-H1
exchange to ischemic injury were complicated by nonspecific
actions of the Na1-H1 exchange inhibitors, and the role of this
exchanger in myocardial infarction in vivo remains unclear. The
difference in anesthetic agents used in experiments could have
resulted in discrepant findings regarding cardioprotection of
some interventions, such as preconditioning and adenosine
triphosphate–sensitive potassium channel openers.
Methods. Infarction was induced by 30 min of coronary occlu-
sion and 3 h of reperfusion in the rabbit heart. In the first series
of experiments, rabbits were anesthetized with pentobarbital or
ketamine/xylazine. Hoe 642 was injected intravenously 10 min
before ischemia or 5 min before reperfusion. In the second series
of experiments, rabbits received 25 mg/kg body weight of poly-
myxin B (polyB), Hoe 642 plus polyB, preconditioning with 5 min
of ischemia and 5 min of reperfusion plus polyB or precondition-
ing alone before 30 min of ischemia.
Results. In pentobarbital-anesthetized rabbits, 0.3 mg/kg and
0.6 mg/kg of Hoe 642 given before ischemia limited infarct size (as
percent area at risk [%IS/AR]) to 42.7 6 4.4% (SEM) and 26.2 6
5.4%, respectively, from the control value of 55.16 3.5%. However,
injection of Hoe 642 before reperfusion did not change infarct size
(%IS/AR 49.6 6 4.9%, p 5 0.387; power 0.81 for detecting 50%
reduction). Infarct size limitation by the preischemic treatment
with Hoe 642 was similarly observed in the rabbits anesthetized
with ketamine/xylazine. In the polyB-treated rabbits, 0.6 mg/kg of
Hoe 642 significantly limited infarct size (%IS/AR was 28.36 3.8%
with Hoe 642 and 50.1 6 7.5% without Hoe 642), although
preconditioning was blocked by the same dose of polyB (%IS/AR
was 39.3 6 6.1% with polyB and 11.3 6 2.4% without polyB).
Conclusions. Hoe 642 enhanced myocardial tolerance against
infarction, and this enhanced tolerance was not influenced by
anesthetic agents commonly used for infarct size studies. Infarct
size limitation by Hoe 642 was not inhibited by polyB, suggesting
that cardioprotection by Na1-H1 exchange inhibition is not PKC
mediated and thus may be unrelated to preconditioning.
(J Am Coll Cardiol 1997;29:693–701)
q1997 by the American College of Cardiology
In animal models of myocardial infarction, it has been well
established that infarct size after coronary artery occlusion is
determined mainly by three factors: the size of ischemic
myocardial mass, the level of residual blood flow in the
ischemic region (i.e., coronary collateral blood flow) and the
duration of the coronary occlusion (1,2). Clinical findings also
show that these factors critically influence the size of infarct,
and thus the outcome in patients with acute myocardial
infarction (3–5). However, the cellular mechanism of ischemic
myocyte death is not clearly understood. Although an elevation
of the cytosolic free Ca21 level in myocytes during ischemia to
a toxic level (i.e., “Ca21 overload”) has been suggested to be
critical for transition from reversible to irreversible injury (6),
it is still unclear how a Ca21 overload is induced in ischemic
cardiomyocytes. A possible mechanism, which recently re-
ceived much attention, is increased Ca21 entry through the
Na1-Ca21 exchange, secondary to the accumulation of Na1 in
the myocytes (7,8). The intracellular Na1 level rapidly in-
creases after the onset of ischemia, to which the extrusion of
H1 by Na1-H1 exchange, decreased Na1 efflux by Na1-K1
pump and Na1 influx through Na1 channels may be contrib-
utory. If an intracellular Na1 buildup does indeed trigger the
Ca21 overload during ischemia, inhibition of the Na1-H1
exchange would attenuate ischemic myocardial injury. This
hypothesis was supported by the recent findings that Na1-H1
exchange inhibitors suppressed the elevation of intracellular
Na1 during ischemia and improved the postischemic contrac-
tile function in isolated whole hearts and papillary muscle
preparations (8–16). However, the agents used in earlier
studies for inhibiting Na1-H1 exchange (i.e., amiloride and its
derivatives) are not necessarily specific to this antiporter, and
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act on Na1-Ca21 exchange as well as Ca21 and Na1 channels
(17).
Recently, infarct size limitation by a Na1-H1 exchange inhib-
itor was reported in swine models of infarction (18,19). However,
it remains unclear whether this protection is independent of
experimental conditions, particularly in animal species and with
anesthetic agents. These problems are not negligible for assessing
the clinical applicability of Na1-H1 exchange inhibitors, and
actual differences in the infarct size-limiting effect with animal
species and anesthetic agents can be exemplified by adenosine
trisphosphate–sensitive potassium channel (KATP) openers and
ischemic preconditioning (20–25). In the experiments using pen-
tobarbital, KATP openers protected the heart from infarction in
dogs (20) but not in rabbits (21). However, infarct size limitation
by a KATP opener was detected in the rabbit when ketamine/
xylazine was used as the anesthetic drug (24). In contrast,
preconditioning against infarction was more clearly observed in
pentobarbital-anesthetized rabbits compared with those anesthe-
tized by ketamine/xylazine (23,25).
Another intriguing question is the role of PKC in the
mechanism of cardioprotection by Na1-H1 exchange inhibi-
tors. Preconditioning with brief transient ischemia enhances
myocardial resistance against infarction more than any phar-
macologic agent, and the involvement of PKC has been
supported by a number of recent studies, including ours
(26–29). Inhibition of Na1-H1 exchange would reduce Ca21
entry through Na1-Ca21 exchange, which may suppress acti-
vation of calcium-dependent PKC. However, this does not
necessarily exclude the possibility that inhibition of Na1-H1
might result in the enhanced production of a PKC-activating
substance (such as bradykinin) or in the indirect activation of
Ca21-independent PKC.
Accordingly, this study aimed to characterize the effect of a
new Na1-H1 exchange inhibitor, Hoe 642 (30), on myocardial
infarct size in the rabbit. Hoe 642 is highly specific to Na1-H1
exchange type 1 (NHE-1) and does not affect ion channels or
the Na1-Ca21 exchanger (30). In the first series of experi-
ments, we assessed whether Hoe 642 can limit infarct size
under two different anesthetic agents commonly used for
infarct size study. Because the results of pilot experiments
supported the presence of an infarct size-limiting effect by Hoe
642 in the rabbit heart, the possible difference between admin-
istration of this agent before ischemia and that before reper-
fusion was examined. In the second series of experiments,
involvement of PKC in the cardioprotective mechanism of Hoe
642 was examined by an inhibitor of PKC, polymyxin B
(polyB).
Methods
This study conformed to the guidelines of Sapporo Medical
University on animal usage.
Experiment 1: Effect of Hoe 642 on Myocardial
Infarct Size
Surgical preparation. Male albino rabbits (Japanese
white) weighing 2.1 to 2.5 kg were anesthetized with pentobar-
bital sodium in Protocol 1 or with ketamine/xylazine in Protocol
2. Pentobarbital sodium was administered as a slow bolus
injection of 40 mg/kg body weight, and an additional small
bolus (;4 mg/kg) was given when necessary. A ketamine/
xylazine injection (a mixture of 10 mg/ml of ketamine and 5
mg/ml of xylazine) was first given as a 1.0- to 1.5-ml bolus to
introduce anesthesia and was then continuously infused at
;0.06 to 0.10 ml/min to maintain anesthesia at a sufficient level
to abolish the corneal reflex. The rabbit was tracheostomized
and ventilated with a Harvard rodent respirator using oxygen
supplement. The tidal volume was 15 ml, and the ventilation
rate and oxygen flow were adjusted to maintain arterial blood
gasses within the physiologic range. Fluid-filled catheters were
inserted into the carotid artery and jugular vein for monitoring
arterial pressure and infusing drugs, respectively. The chest
was opened through a left thoracotomy, the heart was exposed
and a 4-0 silk thread was passed around the marginal branch of
the left circumflex coronary artery using a tapered needle. The
silk thread was threaded through a small vinyl tube to make a
coronary snare. Precordial electrocardiography was monitored
using bipolar leads corresponding to a CC5 lead. The rabbit
was then heparinized with 1,000 U of heparin, and 10 min was
allowed for stabilization. According to the experimental pro-
tocol (as outlined later), the coronary artery was occluded by
the coronary snare for 30 min and then reperfused. After 3 h
of reperfusion, 2,000 U of heparin was intravenously adminis-
tered, and the heart was excised and processed for postmortem
analysis of infarct.
Postmortem analysis. The excised heart was quickly hung
on a Langendorff apparatus and perfused with saline for about
20 s to wash out the blood in the coronary vessels. The left
marginal branch of the coronary artery was reoccluded, and
then Monastral blue dye was injected into the perfusion line to
negatively mark the area at risk (i.e., the territory of the
occluded coronary branch). The heart was then frozen and
sliced into ;2-mm sections parallel to the atrioventricular
groove. The heart sections were incubated in 1% triphenyltet-
razolium chloride (TTC) solution in phosphate buffer (pH 5
7.4) for 20 min to visualize the infarcts (31). The heart slices
were mounted on a glass press that compressed the slices to
Abbreviations and Acronyms
ANOVA 5 analysis of variance
EIPA 5 ethylisopropyl amiloride
%IS/AR 5 infarct size as percent area at risk
KATP 5 ATP-sensitive potassium channel
MIA 5 methylisobutyl amiloride
NHE-1 5 Na1-H1 exchange type 1
PC 5 preconditioned
PKC 5 protein kinase C
polyB 5 polymyxin B
TTC 5 triphenyltetrazolium
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exactly 2 mm. A clear acetate sheet was placed over the press,
and the infarcts (areas unstained by TTC) and areas at risk
(areas unstained by Monastral blue) were traced. The traces of
infarct and risk areas were enlarged by 200% using a Xerox
copy machine and read by a Macintosh Quadra 840AV com-
puter using a Hewlett Packard ScanJett IICX scanner. The
areas of infarct and risk zones were measured by a NIH Image
1.52, an image analysis program. These areas were then
multiplied by the thickness of the heart slice to calculate their
volume.
Experimental protocol. Protocol 1. In this protocol, rabbits
were anesthetized with pentobarbital and divided into four
groups. The control group was untreated and received 30 min
of coronary occlusion and 3 h of reperfusion. In the Hoe-1
group and the Hoe-2 group, Hoe 642 was injected intrave-
nously 10 min before the coronary occlusion at a dose of
0.3 mg/kg and 0.6 mg/kg, respectively. In the Hoe-reperfusion
group, 0.6 mg/kg of Hoe 642 was administered at 5 min before
reperfusion.
Protocol 2. Rabbits were anesthetized with ketamine/
xylazine in this protocol and subjected to one of three treat-
ments before 30 min of coronary occlusion and 3 h of
reperfusion: the ketamine/xylazine group received no treat-
ment and served as a control, and the Hoe-3 and Hoe-4 groups
were given 0.3 mg/kg and 0.6 mg/kg of Hoe 642, respectively,
10 min before ischemia.
Exclusion criteria. In our laboratory, we excluded rabbits
from infarct size analysis when they developed ventricular
fibrillation that was not defibrillated spontaneously or when
their diastolic blood pressure was not maintained .40 mm Hg
during the reperfusion period. This diastolic blood pressure
criteria is derived from our previous finding that diastolic
blood pressure below this level could induce myocardial ne-
crosis due to myocardial hypoperfusion during reperfusion
(32).
Experiment 2: Effect of Polymyxin B on the Infarct
Size-Limiting Effects of Hoe 642 and
Ischemic Preconditioning
Surgical preparation. Rabbits were anesthetized with pen-
tobarbital sodium (30 mg/kg intravenously) and surgically
prepared as in Experiment 1. Postmortem analyses of the heart
for infarct and risk area size were also performed as in
Experiment 1.
Experimental protocol. Four groups of rabbits were each
subjected to one of four pretreatments and then underwent
30 min of coronary occlusion and 3 h of reperfusion. The polyB
group was given 25 mg/kg of polymyxin B (dissolved in 1 ml of
saline) 5 min before the 30 min of ischemia. In the Hoe/polyB
group, 0.6 mg/kg of Hoe 642 was administered 10 min before
the coronary occlusion, and 25 mg/kg of polymyxin B was given
5 min before the ischemia. The PC/polyB group was precon-
ditioned (PC) with 5 min of ischemia and 5 min of reperfusion
and was also given 25 mg/kg of polymyxin B immediately after
the 5 min of preconditioning ischemia. The PC group received
preconditioning with 5 min of ischemia and 5 min of reperfu-
sion alone before the 30 min of coronary occlusion.
Chemicals. Ketamine and pentobarbital were purchased
from Sankyo-Pharmaceutical Co., Tokyo, and Dai-Nippon
Pharmaceutical Co., Osaka, Japan, respectively. Xylazine and
polymyxin B were obtained from Sigma and Hoe 642 was
kindly provided from Hoechst AG, Germany.
Statistics. Hemodynamic variables were compared be-
tween the groups using two-way repeated measures analysis of
variance (ANOVA). The differences in infarct size data be-
tween the groups were tested by one-way ANOVA. When
ANOVA indicated a significant difference, a multiple compar-
ison was performed using the Newman-Keuls post hoc test.
Regression lines were compared by analysis of covariance. The
difference was considered significant at p ,0.05. All data are
expressed as mean value 6 SEM.
Results
Experiment 1. Exclusion of rabbits. After the exclusion
criteria, one rabbit in the Hoe-1 group, which failed to develop
diastolic blood pressure .40 mm Hg during the reperfusion
period, was excluded from the study. No rabbits developed
irreversible ventricular fibrillation in the present experiments.
Hemodynamic data. Baseline heart rates and mean arterial
pressures were comparable in all study groups in both Protocol
1 and Protocol 2 (Table 1). Figures 1 and 2 show the time
courses of the heart rates and mean arterial pressures in
Experiment 1. In Protocol 1, the heart rate was not significantly
changed after treatment and coronary occlusion/reperfusion
(Fig. 1). The mean arterial pressure was reduced after reper-
fusion, but there was no significant difference between the
groups. Compared with the data in Protocol 1, heart rate and
blood pressure in Protocol 2 were lower by ;40% and 10%,
respectively, but both variables were comparable between the
ketamine/xylazine, Hoe-3 and Hoe-4 groups in Protocol 2.
Although the mean arterial pressure gradually decreased and
the heart rate increased during ischemia and reperfusion in
this protocol (Fig. 2), the diastolic pressure was maintained
.40 mm Hg throughout the reperfusion period in all rabbits,








Control 9 274 6 10 85 6 5
Hoe-1 7 279 6 13 84 6 5
Hoe-2 8 271 6 15 84 6 3
Hoe-rep 9 268 6 11 89 6 4
Protocol 2
Ket/Xy 8 164 6 12 76 6 8
Hoe-3 6 148 6 8 82 6 2
Hoe-4 7 147 6 9 67 6 7
Data are presented as mean value 6 SEM. Ket/Xy 5 ketamine/xylazine;
rep 5 reperfusion.
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except for the one excluded by the exclusion criteria, as
mentioned previously. There was no significant difference in
the time courses of the heart rates and blood pressures
between the three groups.
Infarct size data. Table 2 presents the data of area at risk
and infarct size in Experiment 1. The area at risk sizes were
comparable between the study groups in both Protocol 1 and
Protocol 2. The infarct size as percent area at risk (%IS/AR)
was 55.1 6 3.5% in the control group, and %IS/AR in the
Hoe-1 and Hoe-2 groups (42.7 6 4.4% and 26.2 6 5.4%,
respectively) was smaller than the %IS/AR in the control
group, although the difference achieved statistical significance
only in the Hoe-2 group. In Figure 3, the infarct size was
plotted against the size of area at risk for individual rabbits that
entered Protocol 1. There was a significant correlation between
the infarct size and the area at risk size, and the regression
lines in the Hoe-1 and Hoe-2 groups were shifted significantly
downward to the control regression line. Furthermore, the
y-intercept of the regression line was significantly smaller in
the Hoe-2 group than in the Hoe-1 group (Fig. 3). These
results suggest a dose-dependent infarct size limitation by Hoe
642 administered before ischemia. However, in the Hoe-
reperfusion group, %IS/AR (49.6 6 4.9%) was not signifi-
cantly different (p 5 0.387: power 5 0.81 for detecting 50%
reduction) from the control value, and there was no statistical
difference in the infarct size–risk area size relation between the
Hoe-reperfusion and control groups (Fig. 3). These findings
suggest a failure of Hoe 642 to limit infarct size when this agent
was administered shortly before reperfusion.
In the Hoe-3 and Hoe-4 groups, %IS/AR was 35.3 6 3.7%
and 14.4 6 5.0%, respectively, and the latter was significantly
smaller than the %IS/AR in the ketamine/xylazine group
(%IS/AR 5 42.9 6 7.0%). As shown in Figure 4, the regres-
sion line for the infarct size–risk area size relation in the Hoe-4
group had a significantly smaller slope than that in the
Figure 1. Hemodynamic alterations during ischemia and reperfusion
in Protocol 1 of Experiment 1. The Hoe-1 and Hoe-2 groups received
0.3 mg/kg and 0.6 mg/kg of Hoe 642, respectively. In the Hoe-
reperfusion (rep) group, 0.6 mg/kg of Hoe 642 was administered 5 min
before reperfusion. Base 5 baseline; Tx 5 immediately before the
coronary occlusion (i.e., after treatment); I 5 2 min after the onset of
ischemia; R 5 2 min after the onset of reperfusion.
Figure 2. Hemodynamic alterations during ischemia and reperfusion
in Protocol 2 of Experiment 1. The Hoe-3 and Hoe-4 groups received
0.3 mg/kg and 0.6 mg/kg of Hoe 642, respectively. Base 5 baseline;
Tx5 immediately before the coronary occlusion (i.e., after treatment);
I 5 2 min after the onset of ischemia; R 5 2 min after the onset of
reperfusion. Ket/Xy 5 ketamine/xylazine.









Control 9 0.85 6 0.11 0.48 6 0.08 55.1 6 3.5
Hoe-1 7 0.81 6 0.11 0.36 6 0.07 42.7 6 4.4
Hoe-2 8 0.90 6 0.08 0.25 6 0.07 26.2 6 5.4*
Hoe-rep 9 0.83 6 0.07 0.42 6 0.06 49.6 6 4.9
Protocol 2
Ket/Xy 8 0.66 6 0.12 0.31 6 0.09 42.9 6 7.0
Hoe-3 6 0.69 6 0.10 0.25 6 0.05 35.3 6 3.7
Hoe-4 7 0.88 6 0.24 0.15 6 0.06 14.4 6 5.0†
*p , 0.05 versus control. †p , 0.05 versus ketamine/xylazine. Data are
presented as mean value 6 SEM. AAR 5 area at risk; Ket/Xy 5 ketamine/
xylazine; rep 5 reperfusion.
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ketamine/xylazine group, although there was no statistical
difference in the regression line between the Hoe-3 group and
the ketamine/xylazine group. These results suggest a dose-
dependent infarct size-limiting effect of Hoe 642 in rabbits
anesthetized with ketamine/xylazine, and are consistent with
the findings in Protocol 1 using pentobarbital as an anesthetic
agent.
The mean blood pressure during ischemia tended to be
lower in the groups given 0.6 mg/kg of Hoe 642 (i.e., the Hoe-2
and Hoe-4 groups) than in the control rabbits. However, these
statistically insignificant differences are unlikely to contribute
to infarct size limitation, because %IS/AR did not correlate
with the blood pressure in these two groups (r 5 0.20, p 5
0.697 in Hoe-2 group; r5 0.52, p5 0.229 in Hoe-4 group). The
rate–pressure products were lower and infarct size appeared
smaller in the rabbits in Protocol 2 than in those in Protocol 1.
However, there was no significant correlation between infarct
size and rate–pressure products in the untreated control
animals, the rabbits given 0.3 mg/kg of Hoe 642 or those given
0.6 mg/kg of Hoe 642, even when the data in these two
protocols were pooled (r 5 0.30, p 5 0.054).
Experiment 2. Exclusion of rabbits. In this series of exper-
iments, one rabbit in the PC/polyB group was excluded accord-
ing to the exclusion criteria regarding diastolic pressure during
reperfusion.
Hemodynamic data. As summarized in Table 3, baseline
heart rate and blood pressure were comparable in all four
study groups. As shown in Figure 5, administration of polyB
significantly reduced the arterial blood pressure so that blood
pressure before the coronary occlusion and during reperfusion
was lower in the polyB, Hoe/polyB, and PC/poly B groups than
in the PC group. However, the hypotensive effect of polyB
dissipated over a period of ;40 min after its administration,
and diastolic blood pressure was maintained well above
40 mm Hg in all rabbits, except for the one in the PC/polyB
group excluded by the exclusion criteria. The time courses of
the mean arterial pressure in the PC group were significantly
different from those in the three polyB-treated groups (p ,
0.05 by two-way repeated measures ANOVA). There was a
slight reduction in the heart rate after the polyB injection, but
the intergroup differences in the time courses of heart rate
were not statistically significant.
Infarct size data. Infarct size data in Experiment 2 are
summarized in Table 4. There was no significant difference in
the size of area at risk between the four groups assigned into
Experiment 2. The difference in %IS/AR between the polyB
and PC/polyB groups was not statistically significant (50.1 6
7.5% vs. 39.2 6 6.1%, p 5 0.156: power 5 0.60 for detecting
50% reduction), and the %IS/AR in the PC group (11.3 6
2.4%) was smaller than that in the polyB and PC/polyB groups.
Figure 6 presents the infarct size–risk area size relation in the
rabbits in Experiment 2, as well as in the untreated control
animals in Experiment 1. Because there was no significant
difference in the %IS/AR and in the regression relation in the
polyB and control groups, the data in these two groups were
pooled to obtain the control regression line. In Figure 6, the
distribution of data in the PC/polyB group was almost super-
imposable the data in the polyB and the control groups. These
results confirmed the earlier findings by Ytrehus et al. (26) in
Figure 3. Scatterplot of infarct size versus the size of area at risk.
There was a significant linear correlation between the infarct size and
the area at risk in all groups. The regression line in the Hoe-
reperfusion group is not depicted in the figure. The y-intercepts in the
regression lines in the Hoe-1 and Hoe-2 groups (y 5 0.559x 2 0.092,
r5 0.935; and y5 0.512x2 0.215, r5 0.597) were significantly smaller
than that in the control group (y 5 0.679x 2 0.097, r 5 0.934). The
difference in the regression relation between the control versus
Hoe-reperfusion groups (y 5 0.733x 2 0.185, r 5 0.832) did not reach
statistical significance. Open circles 5 control group; closed trian-
gles5Hoe-1 group; open triangles5Hoe-2 group; open upside-down
triangles 5 Hoe-reperfusion group.
Figure 4. Scatterplot of infarct size against the size of area at risk.
Infarct size was correlated with the size of area at risk in the
ketamine/xylazine group (y 5 0.667x 2 0.132, r 5 0.892) and Hoe-3
group (y 5 0.393x 2 0.023, r 5 0.839), and their regression lines were
not statistically different. However, the slope of the regression line in
the Hoe-4 group (y 5 0.067x 1 0.069, r 5 0.253) was significantly
smaller than that of the regression line in the ketamine/xylazine group.
Open circles 5 ketamine/xylazine group; closed triangles 5 Hoe-3
group; open triangles 5 Hoe-4 group.







PolyB 5 284 6 10 98 6 6
Hoe/polyB 6 271 6 14 94 6 3
PC/polyB 5 285 6 24 96 6 4
PC 6 270 6 5 89 6 4
Data are presented as mean value 6 SEM. PC 5 preconditioning; polyB 5
polymyxin B.
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that this PKC inhibitor blocked the protection of precondition-
ing against infarction. In contrast, the %IS/AR in the Hoe/
polyB group was 28.3 6 3.8%, which was significantly lower
than the %IS/AR in the polyB group. Furthermore, the infarct
size–risk area size relations in the Hoe/polyB groups were
shifted significantly downward to the control regression line
(Fig. 6). These findings suggest the presence of a protective
effect of Hoe 642 against infarction in polyB-treated rabbits.
Discussion
The present study showed that a new Na1-H1 exchange
inhibitor, Hoe 642, limits infarct size in the rabbit anesthetized
with pentobarbital and ketamine/xylazine. This infarct size-
limiting effect of Hoe 642 was dose dependent, and the effect
was clearly observed when it was given before the onset of
ischemia but not shortly before reperfusion. Polymyxin B
inhibited the infarct limitation by ischemic preconditioning,
but protection by Hoe 642 was not blocked by this PKC
inhibitor. These findings suggest that Hoe 642 enhances myo-
cardial tolerance against infarction to almost the same extent
as preconditioning, but their mechanisms may be quite differ-
ent with regards to the requirement of PKC activity.
Cardioprotection by Hoe 642 and anesthetic agents. In
screening pharmacologic agents for clinical application, it is
obviously desirable to perform the experiments without anes-
thetic agents because they may interfere with the action of the
agents to be tested. Unfortunately, when infarct size is used as
the end point of ischemic injury, it is not practically easy to
assess the cardioprotective effects of drugs in unanesthetized
animals. Although interaction between anesthetic agents and
cardioprotective agents has not been frequently noted, it was
recently demonstrated for ischemic preconditioning and KATP
openers, which have received much attention because of their
potent anti-infarct actions. Haessler et al. (23) showed that
infarct size limitation by preconditioning in rabbits anesthe-
tized with ketamine/xylazine was 40% of that in pentobarbital-
anesthetized rabbits. In contrast, a KATP opener, pinacidil,
did not cause a significant change in the infarct size in
pentobarbital-anesthetized rabbits (21) but did limit the infarct
size to ;60% of the control value in rabbits anesthetized with
ketamine/xylazine (24). These modifications of precondition-
ing and pinacidil by the anesthetic agents (21–25) have not
Figure 5. Hemodynamic alterations by drug treatments and ischemia/
reperfusion in Experiment 2. Injection of polymyxin B (polyB,
25 mg/kg), Hoe 642 (0.6 mg/kg) plus polymyxin B, preconditioning
(PC) with 5 min of ischemia and 5 min of reperfusion plus polymyxin
B or preconditioning with 5 min of ischemia and 5 min of reperfusion
alone. *p , 0.05 versus the polyB, Hoe/polyB and PC/polyB groups by
two-way repeated measures analysis of variance. Base 5 baseline;
Tx5 immediately before the coronary occlusion (i.e., after treatment);
I 5 2 min after the onset of ischemia; R 5 2 min after the onset of
reperfusion.








PolyB 5 1.15 6 0.20 0.56 6 0.11 50.1 6 7.5
Hoe/polyB 6 0.94 6 0.06 0.27 6 0.04* 28.3 6 3.8*
PC/polyB 5 0.83 6 0.11 0.34 6 0.10 39.2 6 6.1
PC 6 0.83 6 0.10 0.10 6 0.02* 11.3 6 2.4*†
*p, 0.05 versus polymyxin B. †p, 0.05 versus preconditioning/polymyxin B.
Data are presented as mean value 6 SEM. AAR 5 area at risk; PC 5
preconditioning; polyB 5 polymyxin B.
Figure 6. Scatterplot of infarct size versus the size of area at risk.
Because there was no significant difference in the infarct size–risk area
size relation between the polymyxin B (polyB) and control groups,
their data were pooled to calculate the control regression line (y 5
0.486x1 0.046, r5 0.791, p, 0.05). Regression lines in the Hoe/polyB
(y 5 0.525x 2 0.221, r 5 0.771) and preconditioned (PC) groups (y 5
0.15x 2 0.028, r 5 0.519) were shifted significantly downward com-
pared with the control regression line (p , 0.05 for y-intercepts).
Although the regression line in the PC/polyB group is not depicted in
the figure, it was not statistically different from the control regression
line. Open circles 5 control group; closed circles 5 polyB group; open
triangles 5 PC group; open upside-down triangles 5 Hoe/polyB
group; closed triangles 5 PC/polyB group.
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been clearly explained but indicate that caution is needed in
assessing the clinical efficacy of anti-infarct interventions. In
the present study, Hoe 642 limited the infarct size in a
dose-dependent manner in rabbits anesthetized with either
pentobarbital or ketamine/xylazine. The extent of infarct size
limitation by Hoe 642 was comparable for the same dosage,
whereas heart rate and blood pressure were 40% and 10%
lower, respectively, in the ketamine/xylazine-anesthetized rab-
bits than in rabbits anesthetized with pentobarbital. Further-
more, there was no correlation between the rate–pressure
product and infarct size in Hoe 642–treated and nontreated
rabbits. These results suggest that the infarct size-limiting
effect of Hoe 642 is not influenced by myocardial oxygen
consumption or by at least two commonly used anesthetic
agents. Obviously, assessment of the infarct size-limiting effect
of this agent in unanesthetized conscious animals would be the
next step of investigation.
Hoe 642 as an agent that inhibits Na1-H1 exchange. The
possible contribution of Na1-H1 exchange to ischemic myo-
cardial injury has been studied by using several structurally
different inhibitors. In isolated heart preparations, pretreat-
ment of the heart with amiloride or its derivatives, including
ethylisopropyl amiloride (EIPA), methylisobutyl amiloride
(MIA) and 5-N,N-dimethyl amiloride, has been shown to
significantly improve the contractile function after global isch-
emia (8–16). Unfortunately, it does not totally exclude the
possibility that this beneficial action of amiloride derivatives
may be attributable to their actions, other than the inhibition
of Na1-H1 exchange, such as the inhibition of Na1-Ca21
exchange, sodium pump and Na1 channel (17,33,34). How-
ever, a recent study by Hendrikx et al. (15) showed that a more
specific Na1-H1 exchange inhibitor, Hoe 694, also attenuates
the contractile dysfunction after ischemia/reperfusion. The
specificity of Hoe 642 used in the present study for Na1-H1
exchange is comparable to Hoe 694, and the action of Hoe 642
on this exchanger is about four times more potent than Hoe
694 (30). The Ki of Hoe 642 for NHE-1 was 0.05 mmol/liter
(30), which is approximately one-seventh of that of EIPA (Ki5
0.375 mmol/liter), indicating that it is over 1,000 times more
potent for the exchange than amiloride. In addition, Hoe 642
does not act on Na1 and Ca21 channels or the Na1-Ca21
exchanger, in contrast with amiloride derivatives (30). Taken
together, the present results support the hypothesis that inhi-
bition of Na1-H1 exchange enhances myocardial tolerance
against infarction, although a relation between Na1-H1 ex-
change activity and anti-infarct resistance of the myocardium
could not be directly demonstrated.
Effect of Hoe 642 on “reperfusion injury.” It has been
speculated that activation of Na1-H1 exchange contributes
not only to ischemic myocardial injury, but also to “reperfusion
injury.” Reperfusion of an ischemic myocardium washes out
protons from the cardiac interstitium, which would facilitate an
H1 extrusion through the Na1-H1 exchange and consequently
a Ca21 overload through the Na1-Ca21 exchange. This hy-
pothesis is supported by three lines of evidence. First, it has
been shown that there is a close correlation between the
intracellular Na1 level during myocardial ischemia and the
amount of Ca21 influxed during reperfusion (8,11,12). Second,
reperfusion of the ischemic heart with acidic perfusate for the
first 10 to 20 min of the reperfusion period attenuates the
postischemic contractile dysfunction (35,36). Third, in some
studies (8,10,14), treatment of the heart with Na1-H1 ex-
change inhibitors only during the reperfusion period improved
contractile function after ischemia. However, it is not clear
whether activation of Na1-H1 exchange on reperfusion does
indeed kill substantial amount of myocytes. It is possible that
the improvement of postischemic contractile function reflects
attenuation of stunning in the salvaged myocardium without
any change in the mass of ischemic necrosis. Indeed, studies by
Karmazyn (9), Murphy et al. (11), Moffat and Karmazyn (13)
and Myers et al. (16) showed that there was no difference in
creatine kinase release during reperfusion between amiloride-
or MIA-treated hearts and nontreated hearts, although these
Na1-H1 exchange inhibitors improved the recovery of ventric-
ular function from global ischemia. In the present study, we
assessed the effect of the administration of 0.6 mg/kg of Hoe
642 5 min before reperfusion. This protocol allows Hoe 642 to
reach the ischemic myocardium only after reperfusion, because
coronary collateral blood flow is negligible in the rabbit (37). In
contrast with significant infarct size limitation by preischemic
administration of Hoe 642, injection of this agent shortly
before reperfusion failed to protect the myocardium from
infarction. These results are consistent with the findings of
Klein et al. (18), who used Hoe 694 to inhibit Na1-H1
exchange. In their study, intravenous injection of 3 mg/kg of
Hoe 694, 10 min before ischemia significantly limited infarct
size after 45 min by 80% in swine hearts. However, when the
same dose of Hoe 694 was administered 10 min before
reperfusion, infarct size was only 15% less than the control
value, which was not a statistically significant difference. How-
ever, Rohmann et al. (19) recently reported that 7 mg/kg of
Hoe 694 for 15 min administered before reperfusion could
reduce the size of infarct after 60 min of ischemia by 51% in a
swine model of infarction. Although the reason for these
conflicting findings concerning the effect of Na1-H1 exchange
inhibitors administered on reperfusion is unclear, two meth-
odologic differences may be involved. First, the agents (i.e.,
Hoe 694 and Hoe 642) and the dose of Hoe 694 were different
in the three studies, which might have caused differences in the
extent of inhibition of Na1-H1 exchange in the heart. Second,
the duration of myocardial ischemia was different: 30 min in
the present study, 45 min in the study by Klein et al. (18) and
60 min in the study by Rohmann et al. (19). This resulted in
infarct sizes of ;50%, 65% and 78% of the area at risk in
untreated animals. The relative contribution of Na1-H1
exchange-mediated reperfusion injury to the whole infarct size
might be different depending on the duration of myocardial
ischemia. In other words, there may be a time window of
ischemia duration for substantial infarction owing to Na1-H1
exchanger activity during reperfusion. Nevertheless, the situa-
tion in which Na1-H1 exchange predominately contributes to
myocardial necrosis warrants further investigation.
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Role of protein kinase C: preconditioning versus Hoe 642.
It has been confirmed that preconditioning with brief ischemia
markedly enhances myocardial resistance against ischemic
injury (25–27,38–41). This cardioprotection has been sug-
gested to be triggered by the activation of adenosine (38,39),
bradykinin (40,41) and opioid receptors (42,43). Although
subcellular mechanisms subsequent to the activation of these
receptors remain unclear, the involvement of PKC in precon-
ditioning was indicated in several studies using rabbit and rat
models of infarction (26,28,29,41,44,45). Infarct size limitation
by preconditioning was blocked by structurally different PKC
inhibitors (26,44,45), and conversely, PKC activators (26) and
agonists of PKC-linked receptors (28,29,41) could mimic pre-
conditioning. However, the role of PKC in preconditioning is
still controversial and may not be the same in different models
of myocardial ischemia, because preconditioning in canine (46)
and swine (47) hearts was not modified by PKC inhibitors.
Nevertheless, administration of Hoe 642 before ischemia lim-
ited infarct size by .50% in the rabbit (Table 2), which is a
similar level of cardioprotective potency as preconditioning
with 3 min of ischemia (25). Accordingly, Experiment 2 in the
present study examined the hypothesis that inhibition of
Na1-H1 exchange during ischemia might lead to the activation
of an isoform of PKC, and thus enhancement of ischemic
tolerance against infarction. However, polyB, which could
inhibit preconditioning, failed to abolish the infarct size-
limiting effect of Hoe 642 (Fig. 6). This finding suggests that
PKC activity may be unrelated to cardioprotection by inhibi-
tion of Na1-H1 exchange before ischemia, although the
validity of this interpretation is limited by the lack of direct
data on PKC activity and inhibition of Na1-H1 exchange.
There is also the converse possibility that PKC activation might
inhibit Na1-H1 exchange, leading to cardioprotection. How-
ever, this possibility is argued against by two lines of evidence.
First, a PKC-activating phorbol and alpha-adrenoceptor ago-
nist accelerate the Na1-H1 exchange in isolated rat cardiomy-
ocytes (48), although PKC may inhibit Na1-H1 exchange in
noncardiac tissue (49). Second, studies using nuclear magnetic
resonance spectroscopy showed that the elevation of intracel-
lular Na1 during ischemia was not reduced, but rather was
unchanged (50) or even enhanced (51) in the preconditioned
myocardium. These findings are in contrast with results of
studies showing attenuation of Na1 accumulation in hearts
pretreated with Na1-H1 exchange inhibitors (11,12). Further-
more, a recent study by Bugge and Ytrehus (52) showed that
preconditioning and EIPA had an additive infarct size-limiting
effect in isolated rat hearts. Taken together, it appears that the
cellular protective mechanism of the Na1-H1 exchange inhib-
itor is unrelated to ischemic preconditioning.
Conclusions. Myocardial tolerance against infarction was
markedly enhanced by treatment with Hoe 642 before the
onset of ischemia. In contrast with ischemic preconditioning,
this protection by Hoe 642 was similarly observed under
pentobarbital and ketamine/xylazine anesthesia, and it was not
abolished by polyB. Thus, the cellular mechanism of protection
by Na1-H1 exchange inhibition may be unrelated to that of
ischemic preconditioning.
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